Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.
Aphria Inc. (APHA-T; APHA-N) announced that its German subsidiary Aphria Deutschland GmbH has secured the previously announced license for the domestic cultivation of medical cannabis from the German Federal Institute for Drugs and Medical Devices (BfArM), “following the conclusion of a mandatory 10-day standstill period for public contracts.”
Aphria said it was granted a cultivation license for four of the nine total lots awarded by BfArM “and is awaiting the completion of the tender process for the four remaining lots under review, one of which was provisionally awarded to Aphria Germany.”
Wayland Group (WAYL-C) issued a release after markets closed on Thursday to expand on an update it provided on April 17 “with respect to the ongoing process for domestic cultivation of medical cannabis in Germany.”
“The company would like to clarify that Wayland’s joint venture with Demecan GmbH received a score of 60/60 for quality and 40/40 for pricing in the original tender process from early in 2018. Notwithstanding the challenge to the most current tenders described in the update, the company is confident that Demecan will be successful, and will be awarded the 3 lots for production,” it stated.
Cannabis One stated that it will acquire Nevada State-issued cannabis cultivation and manufacturing licenses, held by NV 3480 Partners LLC and 3480 Hacienda Partners LLC, respectively, and related infrastructure, in addition to the flower brand “Fleur” and the cannabis-infused product brands, “Evergreen Organix” and “EG.O.”